PET/MRI in Oncology¹⁸F-FDG · ⁶⁸Ga-tracers

Quick Answer

PET/MRI pairs the molecular signal of PET with the superior soft-tissue contrast and functional MRI sequences (diffusion, dynamic contrast) of MR, at a substantially lower radiation dose than PET/CT because no CT is acquired. Its advantages are concentrated where MRI is already the anatomic modality of choice: pelvic cancers (prostate, cervix, rectum, gynecologic), liver lesions, head-and-neck, brain, bone-marrow disease, and pediatric oncology (where cumulative dose matters most). Its trade-offs are real: longer exams, higher cost, limited availability, weaker performance for small lung nodules (MR is poor in aerated lung), and a distinctive class of MR-based attenuation-correction (MRAC) artifacts — MR does not measure electron density directly, so bone and metal can be mis-segmented and quantitation must be interpreted with that in mind.

Where PET/MRI wins

The gain over PET/CT is greatest where the anatomic read depends on soft-tissue contrast:

The attenuation-correction caveat

CT gives a direct electron-density map for attenuation correction; MR does not — MRAC segments tissue classes (air, lung, fat, soft tissue, and sometimes bone) from MR signal. Consequences: cortical bone may be under-corrected (affecting SUV in/near bone), metal implants and dental hardware create signal voids and susceptibility artifacts, and truncation at the arms/body edge can occur. SUV values are generally usable but are not always interchangeable with PET/CT SUVs, so response comparisons should stay on the same platform where possible.

Practical positioning

PET/MRI is not a wholesale replacement for PET/CT; it is a problem-solver and a dose-sparing option. Choose it when the local/anatomic question benefits from MRI (pelvis, liver, head-and-neck, brain, marrow) or when cumulative dose is a priority (children, young patients, serial imaging). Choose PET/CT for whole-body staging where lung assessment is important, for speed/availability, and for consistent SUV trending. Workflow considerations — longer table time, MR safety screening, and coil/positioning — factor into selection.

High-Yield Pearls

• PET/MRI's edge is soft-tissue contrast + lower dose; it shines in pelvis, liver, H&N, brain, marrow, and pediatrics.
• No CT means less radiation — the biggest advantage for children and serial imaging.
• MRAC infers attenuation from tissue segmentation, not electron density → bone/metal artifacts and SUVs not always interchangeable with PET/CT.
• Small lung nodules are a relative weakness (poor MR signal in aerated lung).

Common Pitfalls

• Directly comparing an MRAC-based SUV to a prior PET/CT SUV as if identical.
• Relying on PET/MRI for small pulmonary nodules.
• Ignoring metal/dental MRAC artifacts that distort nearby quantitation.

Related Pages

• Pitfalls: Attenuation artifacts; overview: FDG PET/CT in oncology.

Self-Check

Key References

• Reviews and society guidance on clinical PET/MRI applications and MR-based attenuation correction.
• Pediatric PET/MRI dose-reduction literature; comparative PET/MRI vs PET/CT accuracy by tumour site.